These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19749489)

  • 41. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 42. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
    Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
    Jabbour E; Cortés JE; Kantarjian H
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S75-81. PubMed ID: 19254884
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Mathisen MS; O'Brien S; Thomas D; Cortes J; Kantarjian H; Ravandi F
    Curr Hematol Malig Rep; 2011 Sep; 6(3):187-94. PubMed ID: 21660654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
    Sun A; Akin RS; Cobos E; Smith J
    J Drugs Dermatol; 2009 Apr; 8(4):395-8. PubMed ID: 19363859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ponatinib for chronic myeloid leukemia.
    Goldman JM
    N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
    [No Abstract]   [Full Text] [Related]  

  • 47. Dasatinib: for some difficult cases of adult leukaemia.
    Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
    [No Abstract]   [Full Text] [Related]  

  • 48. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New insights into small-molecule inhibitors of Bcr-Abl.
    Schenone S; Bruno O; Radi M; Botta M
    Med Res Rev; 2011 Jan; 31(1):1-41. PubMed ID: 19714578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 52. Tyrosine kinase inhibitors in hematological malignancies.
    Kosior K; Lewandowska-Grygiel M; Giannopoulos K
    Postepy Hig Med Dosw (Online); 2011 Dec; 65():819-28. PubMed ID: 22173446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dasatinib suppresses in vitro natural killer cell cytotoxicity.
    Blake SJ; Bruce Lyons A; Fraser CK; Hayball JD; Hughes TP
    Blood; 2008 Apr; 111(8):4415-6. PubMed ID: 18398058
    [No Abstract]   [Full Text] [Related]  

  • 54. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E
    Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
    Kroll T; Ames MB; Pruett JA; Fenske TS
    Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520
    [No Abstract]   [Full Text] [Related]  

  • 56. T315I, more or less, predicts for major molecular response: the devil is in the details!
    Mauro MJ
    Haematologica; 2013 May; 98(5):665-6. PubMed ID: 23633541
    [No Abstract]   [Full Text] [Related]  

  • 57. [Dasatinib is an efficient therapy for central nervous system Philadelphia chromosome-positive mixed phenotype acute leukemia].
    Lin D; Zhou C; Liu B; Lyu R; Wang J; Mi Y; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):1016-7. PubMed ID: 25417882
    [No Abstract]   [Full Text] [Related]  

  • 58. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.
    Yeung DT; Moulton DJ; Heatley SL; Nievergall E; Dang P; Braley J; Branford S; Moore S; Mullighan CG; Hughes TP; White DL
    Leukemia; 2015 Jan; 29(1):230-2. PubMed ID: 25179732
    [No Abstract]   [Full Text] [Related]  

  • 59. [New horizon of chronic myelogenous leukemia].
    Tauchi T; Ohyashiki K
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():617-21. PubMed ID: 17474470
    [No Abstract]   [Full Text] [Related]  

  • 60. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
    Abdelhalim A; Barcos M; Block AW; Sait SN; Starostik P; Wetzler M; Wang ES
    Leuk Lymphoma; 2007 May; 48(5):1053-6. PubMed ID: 17487757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.